- The shares of BioLife have sold off last month, and those of competitor CryoPort much more, closing what we thought was an irrational valuation gap.
- Critics argue that this is a commodity business but we see little or no signs of that.
- The big money is in their clients reaching commercial production after FDA approval, CryoPort simply got more lucky here compared to BioLife, but it will happen there as well.
- The near certainty of increasing commercial scale customers is also why these companies deserve high valuation multiples.
BioLife Gives Another Opportunity To Investors
October 25th, 2019 · No Comments